Last updated: June 6, 2026
Paratek Pharmaceuticals’ competitive position is concentrated in infectious-disease antibiotics and anti-infectives, with a portfolio anchored by its FDA-cleared/late-stage asset history in acute bacterial skin and skin structure infections (ABSSSI) and by platform adjacencies around cephalosporin-like and other antibacterial mechanisms. The patent estate and FDA exclusivity posture for each key asset drive the practical timing of generic entry risk, Paragraph IV exposure, and license strategy, with the highest near-term decision sensitivity tied to (1) product-specific Orange Book status, (2) method-of-use and formulation patent coverage, and (3) litigation posture in the FDA pathway.
What is Paratek Pharmaceuticals’ market position in antibiotics and anti-infectives?
Paratek’s market position is best characterized by narrow but high-value specialty infectious disease exposure rather than broad primary care penetration. The company’s competitive set includes large-cap antibiotic franchises and specialty-to-mid-cap antibiotic developers, where price, formulary adoption, and stewardship alignment determine share after launch.
Which therapeutic areas does Paratek compete in?
- Acute bacterial infections with emphasis on hospital-facing and high-acuity settings.
- ABSSSI and related inpatient/outpatient acute bacterial indications, where outcomes, dosing convenience, and payer contracting are decision drivers.
- Broader anti-infective competition that overlaps with glycopeptides, oxazolidinones, lipopeptides, and next-gen cephalosporins depending on mechanism and label.
How does Paratek’s commercial model differ from big-pharma antibiotics?
- Big-pharma antibiotic franchises typically compete through global scale, payer leverage, and established hospital relationships.
- Paratek competes through targeted clinical value and partnership or co-promotion routes (where applicable), with product positioning tuned to specific payer formularies and stewardship protocols.
What patents protect Paratek’s key antibiotic products?
Patent coverage for Paratek’s competitive edge is asset-specific and is typically split across:
- composition claims (drug substance, prodrug/salt forms where relevant),
- formulation claims (solid state, film coatings, excipient systems, particle size or polymorph),
- method-of-use claims (indication-specific dosing and regimen),
- manufacturing method claims (process steps, intermediates, impurity controls),
- regulatory exclusivity that can extend practical market protection even when some claims expire.
How many patents cover Paratek’s leading compounds, and who owns them?
A full count and mapping requires direct Orange Book and patent-list extraction per NDA for each Paratek product. Without the underlying NDA-level and patent-number-level records, a quantified “how many patents cover” answer cannot be stated accurately.
What formulation patents are commonly asserted in Paratek-style antibiotic portfolios?
In antibiotic portfolios generally, the formulation layer frequently includes:
- excipients and fill composition specific to stability and reconstitution performance,
- solid-state and polymorph control (where applicable),
- particle size or dissolution-rate limitations that tie to bioavailability and tolerability,
- administration-specific formats (e.g., sterile lyophilized powder versus ready-to-use),
- manufacturing-specific impurity specs that support process validity.
What method-of-use patents matter for generic entry risk?
For multi-indication antibiotics, method-of-use patents can be the dominant lever:
- claimed dosing regimens that are tied to the label,
- administration timing schedules,
- patient subgroup definitions (where claims map to specific label text).
What is the Orange Book status of Paratek’s main products?
Orange Book status determines whether an ANDA must address listed patents and whether a Paragraph IV certification is legally viable. The practical impact is simple: where an NDA lists patents covering the active ingredient and the approved formulation, generics typically face a patent thicket at launch.
A product-by-product Orange Book table cannot be produced here because the NDA/patent-list inputs are not provided, and a non-cited listing would not meet the requirement for hard, verifiable data.
When does Paratek lose exclusivity, and what dates control generic launch risk?
Exclusivity and patent expiration together set the entry window. For each Paratek asset, the control points usually include:
- patent expiration of active ingredient composition,
- patent expiration for formulation and manufacturing,
- expiration of method-of-use coverage,
- regulatory exclusivity end dates (including any 5-year/7-year exclusivity triggers and pediatric extensions where present),
- “triggering event” dates tied to NDA supplements that may reset exclusivity for new indications, formulations, or pediatric subsets.
A calendar with exact dates cannot be accurately stated without the NDA numbers and the specific listed patents/exclusivity terms.
Which Paragraph IV challenges affect Paratek, and when do they typically occur?
Paragraph IV challenges create the litigation and 30-month stay dynamics. In antibiotics, challengers often target:
- formulation patents to enable a bioequivalent product with different excipient systems,
- method-of-use patents tied to specific label indications,
- manufacturing-process claims to reduce residual impurity and align to release specs.
A litigation timeline for Paratek cannot be generated without the case dockets and Orange Book patent list linkages for each asset.
What patent litigation affects Paratek Pharmaceuticals and its competitors?
Patent litigation affects:
- whether a generic receives a 30-month stay,
- the scope of settlement (carve-outs, authorized generics, launch commitments),
- the strength of the invalidity/unenforceability defenses.
A litigation-and-settlement section needs:
- case caption(s),
- district court(s),
- asserted patents and claims,
- settlement dates and terms (including scope and whether launch is authorized),
- any subsequent appellate or re-litigation events.
No such hard dataset is present in the prompt, so a correct litigation status table cannot be provided.
How does Paratek’s patent estate strength compare with other antibiotic companies?
Competitive strength in antibiotics is often driven by:
- duration of enforceable claims (earlier composition versus later formulation or method-of-use),
- claim breadth and “design-around” feasibility,
- litigation outcomes (ex: early summary judgment versus protracted claim construction),
- freedom to operate for follow-on dosage forms or combination products.
Without Paratek’s asset-specific patent map, any quantified comparison versus specific peers would be incomplete and would risk inaccuracies.
What formulations are protected by Paratek, and how does that block generic switching?
For injectable and reconstituted antibiotics, formulation patents can block:
- direct ANDA-to-ANDA substitution,
- label-aligned dosing changes that would allow “non-infringing” workarounds,
- generic manufacturers’ ability to produce the same stability and impurity profile with alternative processes.
A formulation-protection inventory requires:
- the specific dosage forms (injectable versus oral),
- the NDA listing of formulation patents,
- the asserted claim types in litigation.
No Orange Book patent list details are provided here.
What generic entry risks exist for Paratek’s antibiotics?
Generic entry risk is a function of:
- proximity to expiration,
- whether the remaining enforceable patents cover the active ingredient or only downstream formulation/method-of-use,
- litigation intensity and settlement posture,
- whether generics can legally launch “at risk” without waiving or carving around indication-specific claims.
A credible, product-level generic entry risk assessment requires Orange Book and litigation record inputs not included in the prompt.
What biosimilar risk exists for Paratek Pharmaceuticals?
Biosimilar risk applies only if Paratek’s core assets are biologics (monoclonal antibodies, cytokines, fusion proteins, or other FDA-licensed biologics). Paratek is not known for a biologics-heavy portfolio in the way that major biosimilar competitors face biosimilar displacement. Absent a biologics product list in the prompt, a biosimilar-risk section cannot be grounded in accurate asset-level facts.
How does Paratek compare with leading antibiotic competitors on patent strategy?
Patent strategy among antibiotic companies typically splits into:
- early composition protection,
- late-cycle formulation and method-of-use layering to extend practical exclusivity,
- separate patent families covering different solid-state forms or manufacturing processes.
A Paratek-to-peer comparison requires peer asset patent maps and Paratek’s own estate data at the family and claim-type level. The prompt provides no such identifiers.
What manufacturing and process patents could restrict Paratek generics?
Manufacturing patents can restrict generic supply in three ways:
- process claims that are hard to design around,
- intermediate-specific claims that constrain synthesis routes,
- impurity-control claims tied to release testing, which drive the ability to meet NDA specs.
A process-patent barrier analysis needs Paratek’s manufacturing method patent numbers and assignees, plus whether they are listed in the Orange Book (or litigated in court).
Commercial exposure: what portion of opportunity depends on protected indications?
In antibiotics, revenue exposure usually correlates to:
- the portion of sales tied to label indications covered by method-of-use patents,
- the portion tied to a specific formulation or dosing presentation,
- whether payers restrict use based on stewardship and clinical pathway inclusion.
A quantified commercial exposure estimate cannot be produced without Paratek segment/product sales data and mapping to specific patent coverage.
Key Takeaways
- Paratek’s competitive landscape is driven by asset-level patent and exclusivity timing, particularly in acute-care antibiotic indications where payer and hospital uptake is sensitive to clinical outcomes and access.
- The practical generic-entry window depends on Orange Book-listed patents (composition, formulation, method-of-use, manufacturing) and any Paragraph IV litigation or settlement terms.
- A definitive “strength” score and a litigation-risk timeline require NDA-specific patent list and docket data, which is not included in the prompt.
FAQs
- What drives generic launch timing for antibiotic NDAs with layered formulation and method-of-use patents?
- How do settlement agreements in Paragraph IV cases typically change “at-risk” launch dates for ANDA filers?
- When are method-of-use patents the primary barrier to label-indication substitution in ABSSSI antibiotics?
- What Orange Book patent types most often survive into late-stage antibiotic generic competition?
- How do manufacturing process patents influence generic approval and patent infringement analyses for injectable antibiotics?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed 2026-06-06)
